A novel treatment that uses a disintegrating matrix for sustained release of medication led to improvement in vision and reduced supplemental treatment in patients with diabetic macular edema, ...
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...
After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
The "Diabetic Macular Edema (DME): Epidemiology Forecast to 2034" report has been added to ResearchAndMarkets.com's offering. In the 7MM, the diagnosed prevalent cases of DME in diabetes are expected ...
Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...
Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...
The Ghana FDA’s approval was granted following a rigorous, science-based regulatory review that referenced comprehensive data ...
Ollin Biosciences Inc. is gearing up for global phase III trials this year after disclosing favorable top-line results from its randomized, head-to-head phase Ib Jade study comparing OLN-324, a ...
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
As of Friday, January 09, Coherus Oncology, Inc.’s CHRS share price has surged by 6.86%, which has investors questioning if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback